Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02358889 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

A Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Iconic Therapeutics.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02358889: Completed Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Iconic Therapeutics.

NCT02358889 is a Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization that has completed, run by Iconic Therapeutics. The registered enrollment target is 88 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02358889, a Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization, has completed, sponsored by Iconic Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Primary Outcome

Best corrected visual acuity (BCVA) was measured pre treatment prior to dilating eyes, using standard Early Treatment Diabetic Retinopathy Study (ETDRS) retro illuminated charts. The BCVA was recorded as the total letter score in each eye.

Conditions Studied

Age-related Macular Degeneration Choroidal Neovascularization

Interventions

  • OTHER Sham injection
  • BIOLOGICAL hI-con1
  • BIOLOGICAL ranibizumab

Study Locations (20)

California

  • - Arcadia
  • - Beverly Hills
  • - Campbell
  • - Glendale
  • - Laguna Hills
  • - Mountain View
  • - Palm Desert
  • - Palo Alto
  • - San Francisco
  • - Santa Ana

Florida

  • - Boynton Beach
  • - Fort Myers
  • - Panama City
  • - Sarasota
  • - Stuart
  • - Winter Haven

Arizona

  • - Phoenix
  • - Phoenix

Colorado

  • - Golden

Georgia

  • - Augusta

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2015-02
Est. Completion 2016-09
Phase Phase 2
Iconic Therapeutics

4 total trials

What the finished NCT02358889 record still lists

NCT02358889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Sham injection is the first listed.

NCT02358889 names 20 study sites across 5 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02358889 about?

NCT02358889 is a clinical study titled "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration". The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal n...

What is the current status of trial NCT02358889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2015-02. Estimated completion is 2016-09.

What conditions does trial NCT02358889 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Choroidal Neovascularization.

What interventions are being tested in trial NCT02358889?

The interventions under investigation include: Sham injection (OTHER), hI-con1 (BIOLOGICAL), ranibizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02358889?

This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02358889 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02358889's enrollment target sits among peer trials

88 35th of 74 higher than 40 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02358889, the US trial registry maintained by the National Library of Medicine. NCT02358889 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.